John Deeney, MD
Gynecology · Meadowbrook, PANPI 1124020680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 35.5% of the total. Reporting peaked in 2019 at $354 and has fallen 53.6% since, to $164 in 2025.
Across 68 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$428
- Astellas Pharma US Inc$250
- Therapeuticsmd, Inc.$107
- Amgen$67
- Exeltis, USA Inc.$54
- Daiichi Sankyo Inc.$50
- plus $248 from 12 others
What the payments were for
- Food & beverage$1,19299%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $428 |
| Astellas Pharma US Inc | 12 | $250 |
| Therapeuticsmd, Inc. | 7 | $107 |
| Amgen | 4 | $67 |
| Exeltis, USA Inc. | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Merck | 2 | $33 |
| Hologic Sales And Service, LLC | 2 | $30 |
| Avion Pharmaceuticals | 2 | $27 |
| Pfizer | 1 | $24 |
| Covidien LP | 1 | $23 |
| Millicent US Inc | 1 | $20 |
| Coopersurgical, Inc. | 1 | $19 |
| Mylan Pharmaceuticals Inc. | 1 | $19 |
| GSK | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Minerva Surgical, Inc | 1 | $13 |
| Organon | 1 | $12 |
How this compares
$1,205 in reported general payments places this provider in the 60th percentile of 98 gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 58 | $7,424 |
| Clobetasol Propionate | 33 | $1,644 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $352 |
| Alendronate Sodium | 13 | $261 |
| Fluconazole | 24 | $125 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Meadowbrook
- Jordan KlebanoffNewtown Square$187K
- Harry ReichShavertown$136K
- Gretchen MakaiYork$102K
- Karen TangBryn Mawr$96K
- Joseph TalvacchiaPhiladelphia$85K
- David ToubWyncote$41K
- David EvansCarlisle$30K
- Harold DavisScranton$22K
- Reneita RossPhiladelphia$8K
- Marydonna RavasioButler$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.